Wed, Jul 23, 2014, 3:21 PM EDT - U.S. Markets close in 39 mins.


% | $
Click the to save as a favorite.

Organovo Holdings, Inc. Message Board

rongreen1 3 posts  |  Last Activity: Jul 11, 2014 12:22 AM Member since: Dec 4, 1997
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    $ 15 by year end. who and what can stop ONVO?

    by raj.notary Jul 10, 2014 11:04 PM
    rongreen1 rongreen1 Jul 11, 2014 12:22 AM Flag

    Not a chance of that, author.

  • Presentation Summary:

    The ability to use a common technology platform to develop both therapeutic tissues and preclinical research tissues is immensely attractive. A particularly well-suited approach being developed for and applied to both of these primary outcomes is 3D bioprinting, which allows for computer-based design and automated fabrication of 3D tissue structures using a wide variety of cell and material inputs. Through 3D bioprinting, therapeutic tissues that have been made with common design inputs and limitations can be fabricated with either autologous or allogeneic cells, allowing manufacturing time and cost to be optimized for specific indications. While the most frequently discussed goal for tissue engineering and regenerative medicine is the development of novel tissue-based therapies, the preclinical space is likely to be where the short-term impacts of these disciplines are first realized. The development and fabrication of stable, 3-dimensional, human tissues for use in drug discovery, development and disease modeling presents an opportunity for the industry to access more predictive human preclinical models. Using 3D bioprinting, rapid fabrication of stable, cell-dense, human tissue analogs is possible. within common multi-well plate formats. This approach allows for the interrogation of the tissue following exposure to known or developmental therapeutics, as well as for stimulation of the tissue constructs with factors believed to play key roles in development of tissue pathology. Here we will explore how these challenges are being addressed at large, using examples from our own technology platform and pipeline.

    Presented by:

    Benjamin Shepherd, PhD – Dr. Shepherd has more than 14 years of experience in Tissue Engineering and Regenerative Medicine research. Dr. Shepherd’s research in vascular biology and microvascular tissue engineering has been focused on the ability to use creative approaches to generate microvascular networks to s

  • Reply to

    I increased my position today...

    by henrymorgan_capt May 7, 2014 2:06 PM
    rongreen1 rongreen1 May 7, 2014 10:45 PM Flag

    Aye Aye Captain!

7.69+0.04(+0.52%)3:20 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.